Answers are grounded in this paper and cite their sources.
Monomorphic epitheliotropic intestinal T‐cell lymphoma (MEITL) is a mature T‐cell lymphoma that originates from intestinal intraepithelial T lymphocytes. It is a rare malignancy with a poor prognosis and a median overall survival of only 7 months. Currently, there is no standard treatment regimen for MEITL, and chemotherapy is the most commonly used approach. However, the application of radiotherapy and immunomodulators has rarely been reported. This report describes a case of MEITL in a middle‐aged male. The patient initially received CHOEP (cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone) chemotherapy but failed to complete the planned course owing to Grade IV leukopenia. Subsequently, the patient underwent whole abdominal radiotherapy (WART). After the completion of WART, the patient was continuously administered lenalidomide‐dexamethasone (LenDex). Excellent therapeutic efficacy was achieved, with no evidence of disease confirmed by regular post‐treatment follow‐up and disease‐free survival exceeding 24 months. The combination of WART and LenDex for MEITL has not been previously reported and its potential therapeutic value may provide valuable insights for clinical practice and future research.
No takes yet. Share an insight, caveat, or question.
Wei et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: